What happened
Genome & Company disclosed convertible bonds to raise US$18.2M, about 9.0% of its market value.
For context, this raise equals about 9.0% of the company's market value, which is the rough scale of potential new-share dilution.
| Instrument | Convertible bonds |
|---|---|
| Raise amount | US$18.2M |
| vs. market value | 9.0% |
| Filed | 2026-03-06, Material event report (convertible bonds) |
| Source | DART rcept 20260305001673 → open original filing |
Source: DART. Information only, not investment advice.